ValuEngine downgraded shares of Vericel (NASDAQ:VCEL) from a hold rating to a sell rating in a report issued on Friday.
A number of other brokerages have also recently issued reports on VCEL. BTIG Research reiterated a buy rating and set a $6.00 target price on shares of Vericel in a report on Thursday, September 7th. Piper Jaffray Companies reiterated a buy rating and set a $7.00 target price on shares of Vericel in a report on Thursday, August 10th.
Shares of Vericel (VCEL) opened at $4.50 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.50 and a quick ratio of 2.22. Vericel has a fifty-two week low of $2.25 and a fifty-two week high of $6.30.
Several large investors have recently modified their holdings of VCEL. Bank of New York Mellon Corp grew its holdings in shares of Vericel by 13.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,202 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 4,523 shares during the period. First Washington CORP purchased a new stake in shares of Vericel during the 2nd quarter worth about $2,230,000. Vanguard Group Inc. grew its holdings in shares of Vericel by 7.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock worth $4,002,000 after purchasing an additional 88,645 shares during the period. Archon Capital Management LLC purchased a new stake in shares of Vericel during the 2nd quarter worth about $4,412,000. Finally, Perkins Capital Management Inc. grew its holdings in shares of Vericel by 118.4% during the 3rd quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock worth $3,376,000 after purchasing an additional 305,000 shares during the period. Institutional investors and hedge funds own 33.17% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://weekherald.com/2017/12/04/vericel-vcel-cut-to-sell-at-valuengine.html.
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.